Letairis and Volibris
Two Top 50 pharma companies developed a new asset which would be developed for different regulatory agencies and marketed in different geographic areas. Each name had to go through our exclusive linguistic evaluation process with well-defined guidance to fit the appropriate end result, while also tying the two names together.